In the latest market close, DaVita HealthCare (DVA) reached $137.72, showing a +1.3% movement compared to the previous day, outperforming the S&P 500’s daily gain of 0.64%. However, the stock has fallen by 3.75% in the past month, lagging behind the Medical sector’s gain of 0.71% and the S&P 500’s gain of 3.82%.

Analysts anticipate DaVita HealthCare’s upcoming earnings disclosure with a projected EPS of $2.47, a 18.75% increase from the previous year. Revenue is estimated to reach $3.16 billion, showing a 5.43% increase. For the full year, earnings are projected at $9.62 per share and revenue at $12.74 billion, representing +13.58% and +4.97% changes, respectively.

Investors should pay attention to recent revisions in analyst forecasts for DaVita HealthCare, as they reflect changing business trends. Positive estimate changes indicate a favorable outlook on the company’s health and profitability. The Zacks Rank model, with a rank of #3 (Hold) for DaVita HealthCare, has a history of outperforming expectations in stock returns.

DaVita HealthCare’s current valuation metrics include a Forward P/E ratio of 14.13, below the industry average of 23.15. Its PEG ratio, at 1.04, is lower than the industry’s average of 2.03. The Medical – Outpatient and Home Healthcare industry, part of the Medical sector, holds a Zacks Industry Rank of 60, in the top 24% of all industries.

Zacks has identified a #1 semiconductor stock with significant growth potential in comparison to NVIDIA. The new top chip stock is positioned to cater to the rising demand for AI, ML, and IoT, with the global semiconductor market projected to grow from $452 billion in 2021 to $803 billion by 2028. Investors can access more information and recommendations from Zacks Investment Research.

Read more at Nasdaq: DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts